SBRT 2016

Risk adapted fractionation – Clinical Situation

Prospective Phase II trial Iyenger JCO 2014 • Maximum 5 Platin-resistant sites based on FDG-PET

• SBRT to all progressive sites, • Switch to concurrent Erlotinib

• 24 patients with 52 sites

1 Fx

3 Fx

5 Fx

In-field failure

3 / 21

Physical dose

19 – 24Gy 27 – 33Gy 35 – 40Gy

Out-field failure

10 / 21

No failure

10 / 21

Max BED

82Gy

70Gy

72Gy

 Excellent OS AND local tumor control lower SBRT doses

Matthias Guckenberger - ESTRO SBRT Course 2016 Athens

13.06.2016

25

/